Das kam eben über pubmed zum Thema Operationen von Magencarcinomrezidiven. Kann man natürlich nicht verallgemeinern, aber die Ergebnisse dieser Studie sind natürlich super.
(
http://www.ncbi.nlm.nih.gov/pubmed/1...t=AbstractPlus)
vG,
KL
Surgical treatment of recurrent gastric cancer.De Liaño AD, Yarnoz C, Aguilar R, Artieda C, Ortiz H.
Esophagogastric Unit, Department of General and Gastrointestinal Surgery, Hospital Virgen del Camino, C/ Pintor Maeztu 2, 8 °C, Pamplona, 31008, Navarra, Spain.
BACKGROUND: The value of programs to detect recurrence of a previously operated gastric cancer is a controversial subject. D2 lymphadenectomy achieves better local control and a lower local recurrence rate than D1 lymphadenectomy. METHODS: The results achieved with surgical treatment of recurrent gastric cancer in a series of 126 consecutive patients who had been treated with gastrectomy with D2 lymphadenectomy are reported. In-hospital mortality was 1.6%. RESULTS: Follow-up of the remaining 124 patients for a median period of 73.6 months detected recurrence in 46 patients (37%). There were 14 local, 12 peritoneal, and 15 distant recurrences. Recurrent gastric cancer was detected within 2 years in 76% of the patients. Of the 46 patients with recurrence, 5 patients (11%) were selected for surgery (4 local and 1 peritoneal recurrence). The median disease-free time after surgery for recurrence was 26 months (range, 14-58 months). There was no in-hospital mortality. The median survival time after surgery for recurrence was 26 months (range, 9-87 months). One patient died during follow-up, while none of the other patients have any evidence of new recurrence. CONCLUSION: Surgery for recurrent gastric cancer is a valid alternative in selected patients, provided it is performed by specialized work teams.